ARCHIVES

Pfizer’s Inlyta Gives FDA a Teaching Moment: Not All PFS Advantages Are Created Equal

This article is from The Cancer Letter archive.

Vol. 37 No. 46 | December 16, 2011

Download PDF Visit The Full Archive

Related Articles

In Brief: The Anatomy Of An Administrative Nightmare: How NIH Spent $518 Million In One Day

October 23, 1992

In Brief: McIntyre To Replace Frei As Group Chairman Abeloff, Murphy Nominated For ASCO Presidency

January 26, 1990

Funding Opportunities.

April 12, 2002

Revlimid Extends Time To Progression Compared To Placebo In Phase III Trial

December 25, 2009

Sledge Elected ASCO President

January 16, 2009

Phase III Trial of Talimogene Laherparepvec Meets Response Rate Primary Endpoint

March 29, 2013